Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Oregano and Basil Leaves and Coronary Artery Disease Primary completion pushed from Sep 28, 2026 to Dec 21, 2026
- Minor: Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) Primary and study completion pushed from Oct 2026 to Apr 2027
- Minor: Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study Primary completion pushed from Dec 31, 2026 to May 31, 2027
- Minor: Eye-Tracking Alcohol Warning Primary completion pushed from Oct 1, 2027 to Nov 1, 2027
- Minor: Photoplethysmography-Based Machine Learning Algorithm for Early Atrial Fibrillation Detection: A Prospective Validation Study Primary completion pushed from Aug 2026 to Nov 2026
- Minor: Low or High Dietary Fiber Diet on Volatile Organic Compounds in Exhaled Breath of Healthy Individuals Primary completion pushed from Nov 2026 to Feb 2027
- Minor: Hybrid Breastfeeding Education in Late Pregnancy: Effects on Antenatal Attachment and Breastfeeding Primary completion pushed from Jun 14, 2026 to Sep 12, 2026
- Minor: Can Ultrasound-Guided Fascial Plane Blocks Reduce Postoperative Pulmonary Complications After Major Abdominal Surgery? Primary completion pushed from Aug 1, 2026 to Dec 1, 2026
- Minor: Beamion LUNG-3 · Adjuvant Zongertinib vs Standard Treatment · Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations Trial sites expanded: 202 → 205 locations
- Minor: EloraTZP · Obesity or Overweight and Type 2 Diabetes Trial sites expanded: 75 → 96 locations
- Minor: QTX-2101 · Acute Promyelocytic Leukemia Trial sites expanded: 36 → 39 locations
- Minor: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Trial sites expanded: 314 → 317 locations
- Minor: Ivonescimab for First-line Treatment of Metastatic NSCLC · High PD-L1 Trial sites expanded: 285 → 292 locations
- Minor: Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 66 → 84 locations
- Minor: How a New Pneumococcal Vaccine Works in Infants Trial sites expanded: 130 → 134 locations
- Minor: Ravulizumab · Primary IgAN Trial sites expanded: 15 → 19 locations
- Minor: ELEVATE-LIVER · Survodutide Helps Improve Heart Structure and Function · Overweight or Obesity and Fatty Liver Disease Trial sites expanded: 45 → 55 locations
- Minor: Pegozafermin · Compensated Cirrhosis Due to MASH Trial sites expanded: 330 → 335 locations
- Minor: Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 53 → 60 locations
- Minor: Intravitreal Injection of 4D-150 · Diabetic Macular Edema (DME) Trial sites expanded: 92 → 95 locations
- Minor: KarXT · Manic Episodes in Bipolar-I Disorder (BALSAM-3) Trial sites expanded: 182 → 191 locations
- Minor: Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone · Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP) Trial sites expanded: 3 → 21 locations
- Minor: CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis Trial sites expanded: 35 → 40 locations
- Minor: Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial sites expanded: 28 → 46 locations
- Minor: Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial sites expanded: 10 → 20 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates